Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide plus lifestyle modification in obese children and adolescents with MASLD
IRCT20220409054467N8Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity comparing Liraglutide + lifestyle modification with Placebo + lifestyle modification (2 arms). Primary endpoints: Liver enzymes, Body mass index and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)obesity
Beyond the preview
Go deeper on IRCT20220409054467N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220409054467N8.